Literature DB >> 2764728

Immune responses to wild and vaccine rubella viruses after rubella vaccination.

M G Cusi1, R Metelli, P E Valensin.   

Abstract

Antibody responses to individual structural proteins (E1, E2, and C) of the M33 wild rubella virus and the RA 27/3 live attenuated rubella strain were assayed by immunoblotting in 11 girls, following immunization with RA 27/3 rubella vaccine. Serum samples were drawn before immunization and at 10 days, 1 month, 1 year, 2 years, and 3 years afterwards. All the subjects showed antibodies to E1 glycoprotein of both the virus strains up to three years after immunization, indicating the importance of E1 in immunity. Antibodies to E1 were always present when with neutralizing activity was observed. Antibodies to E2 protein of both the viruses and to the C protein of the M33 virus gradually disappeared with time in some samples, while antibodies to C protein of the RA 27/3 virus strain were found persistently in all the sera.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2764728     DOI: 10.1007/BF01311038

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  28 in total

1.  Rubella virus antigens: localization of epitopes involved in hemagglutination and neutralization by using monoclonal antibodies.

Authors:  K Y Green; P H Dorsett
Journal:  J Virol       Date:  1986-03       Impact factor: 5.103

2.  Synthetic peptides: a next generation of vaccines?

Authors:  M W Steward; C R Howard
Journal:  Immunol Today       Date:  1987

3.  Specific antibody patterns over a two-year period after rubella immunization with RA 27/3 live attenuated vaccine.

Authors:  P E Valensin; G M Rossolini; M G Cusi; A Zanchi; C Cellesi; A Rossolini
Journal:  Vaccine       Date:  1987-12       Impact factor: 3.641

4.  Detection of antibodies to individual proteins of rubella virus.

Authors:  T W Loo; I MacDonald; D M Clarke; M Trudel; A Tingle; S Gilam
Journal:  J Virol Methods       Date:  1986-05       Impact factor: 2.014

5.  Immunologic properties of RA27-3 rubella virus vaccine. A comparison with strains presently licensed in the United States.

Authors:  S A Plotkin; J D Farquhar; P L Ogra
Journal:  JAMA       Date:  1973-08-06       Impact factor: 56.272

6.  New scientific opportunities and old obstacles in vaccine development.

Authors:  K S Warren
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

7.  Structure and function of the rubella virus proteins.

Authors:  P H Dorsett; D C Miller; K Y Green; F I Byrd
Journal:  Rev Infect Dis       Date:  1985 Mar-Apr

8.  Congenital rubella after maternal reinfection.

Authors:  M Forsgren; G Carlström; K Strangert
Journal:  Scand J Infect Dis       Date:  1979

9.  Rubella-associated arthritis: rescue of rubella virus from peripheral blood lymphocytes two years postvaccination.

Authors:  J K Chantler; D K Ford; A J Tingle
Journal:  Infect Immun       Date:  1981-06       Impact factor: 3.441

10.  Postpartum rubella immunization: association with development of prolonged arthritis, neurological sequelae, and chronic rubella viremia.

Authors:  A J Tingle; J K Chantler; K H Pot; D W Paty; D K Ford
Journal:  J Infect Dis       Date:  1985-09       Impact factor: 5.226

View more
  9 in total

Review 1.  Rubella vaccines: past, present and future.

Authors:  J M Best
Journal:  Epidemiol Infect       Date:  1991-08       Impact factor: 2.451

2.  Detection of rubella virus-specific immunoglobulin G (IgG), IgM, and IgA antibodies by immunoblot assays.

Authors:  T Zhang; C A Mauracher; L A Mitchell; A J Tingle
Journal:  J Clin Microbiol       Date:  1992-04       Impact factor: 5.948

3.  Investigation into low-level anti-rubella virus IgG results reported by commercial immunoassays.

Authors:  Wayne Dimech; Nilukshi Arachchi; Jingjing Cai; Terri Sahin; Kim Wilson
Journal:  Clin Vaccine Immunol       Date:  2012-12-19

4.  Expression of recombinant E2 and C proteins of rubella virus in insect cells.

Authors:  M G Cusi; S Bianchi; L Cioè; P E Valensin
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

5.  Possibility of reinfection after immunisation with RA27/3 live attenuated rubella virus.

Authors:  M G Cusi; P E Valensin; C Cellesi
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

Review 6.  Standardization of Assays That Detect Anti-Rubella Virus IgG Antibodies.

Authors:  Wayne Dimech; Liliane Grangeot-Keros; Christelle Vauloup-Fellous
Journal:  Clin Microbiol Rev       Date:  2016-01       Impact factor: 26.132

7.  Characterization of rubella-specific humoral immunity following two doses of MMR vaccine using proteome microarray technology.

Authors:  Iana H Haralambieva; Michael J Gibson; Richard B Kennedy; Inna G Ovsyannikova; Nathaniel D Warner; Diane E Grill; Gregory A Poland
Journal:  PLoS One       Date:  2017-11-16       Impact factor: 3.240

Review 8.  Chemical Modification of Chitosan for Efficient Vaccine Delivery.

Authors:  Lei Xing; Ya-Tong Fan; Tian-Jiao Zhou; Jia-Hui Gong; Lian-Hua Cui; Ki-Hyun Cho; Yun-Jaie Choi; Hu-Lin Jiang; Chong-Su Cho
Journal:  Molecules       Date:  2018-01-25       Impact factor: 4.411

Review 9.  Molecular biology of rubella virus.

Authors:  T K Frey
Journal:  Adv Virus Res       Date:  1994       Impact factor: 9.937

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.